Spruce Biosciences (SPRB) investor relations material

Executive summary

• TA-ERT program for Sanfilippo Syndrome Type B (MPS IIIB) is advancing, with BLA submission and confirmatory study anticipated in Q4 2026 and potential commercial launch in mid-2027.

• No products approved or revenue generated to date; significant net losses and negative cash flows continue.

• April 2026 public offering raised $64.4M; August 2026 private placement and $5.5M strategic investment from advocacy groups support expanded access and clinical programs.

• Leadership strengthened with new Chief Medical Officer and VP of Clinical Development, both with rare disease expertise.

Financial highlights

• Net loss of $16.2M for Q2 2026, up from $2.1M in Q2 2025; six-month net loss of $28.5M, up from $16.1M year-over-year.

• Operating expenses for Q2 2026 were $16.5M, with R&D at $12.2M and G&A at $4.3M; cash and cash equivalents were $96.3M as of June 30, 2026, up from $48.9M at year-end 2025.

• Accumulated deficit reached $317.7M as of June 30, 2026.

• Weighted-average shares outstanding increased to 2.43M in Q2 2026 from 591K in Q2 2025 due to equity financings.

Outlook and guidance

• Cash runway expected to fund operations and debt obligations for at least 12 months from the reporting date and into the second half of 2027.

• Expenses projected to increase as TA-ERT advances through regulatory submission, confirmatory and expanded access studies, and commercialization preparation.

• Additional capital will be required for further development and commercialization efforts.